
07/22/2025
Despite the well-established effectiveness of rifampin as adjunctive therapy for staphylococcal PJI, Kugelman et al. found that only half of patients who met IDSA criteria for starting treatment actually received the medication.
"Given the evidence of superior outcomes for patients treated with adjunctive rifampin, it is imperative that all patients meeting criteria be started on the medication unless there is a clear contraindication, which should be documented," the authors write.
"The findings of this study are important as they suggest that rifampin is not being used enough," writes Timothy Lang Tan MD in a commentary. "In fact, we should look for ways to broaden current indications."
Read the article here: https://ow.ly/9y2450WtzeE
Read the CORR Insights commentary here: https://ow.ly/IHNR50WtzeF